$0.97 EPS Expected for Valeant Pharmaceuticals International, Inc. (VRX); CYREN Ltd. (CYRN) Had 2 Bullish Analysts

February 18, 2018 - By David Stenberg

Among 2 analysts covering CYREN (NASDAQ:CYRN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CYREN had 2 analyst reports since August 24, 2015 according to SRatingsIntel. Craig Hallum initiated the stock with “Buy” rating in Monday, August 24 report. Craig-Hallum initiated it with “Buy” rating and $4 target in Monday, August 24 report. See CYREN Ltd. (NASDAQ:CYRN) latest ratings:

Analysts expect Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report $0.97 EPS on February, 27.They anticipate $0.29 EPS change or 23.02% from last quarter’s $1.26 EPS. VRX’s profit would be $337.80M giving it 4.87 P/E if the $0.97 EPS is correct. After having $1.04 EPS previously, Valeant Pharmaceuticals International, Inc.’s analysts see -6.73% EPS growth. The stock increased 1.12% or $0.21 during the last trading session, reaching $18.88. About 10.17 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since February 18, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.

CYREN Ltd., together with its subsidiaries, provides information security solutions for protecting Web, email, and mobile transactions in the United States, Germany, Europe, Asia, Israel, and internationally. The company has market cap of $102.17 million. The firm offers CYREN WebSecurity, a solution for cloud protection of its customerÂ’s devices against Web-borne threats; CYREN EmailSecurity that frees inboxes of spam, malware, and phishing threats without blocking important business messages; and Cyber Intelligence Suite, which delivers protection from malicious IPÂ’s, phishing attacks, and malware outbreaks. It currently has negative earnings. It also provides CYREN Inbound AntiSpam that allows real-time blocking of spam and phishing in various languages or formats; CYREN Outbound AntiSpam to neutralize spam originating from within a customerÂ’s infrastructure; CYREN Embedded Antimalware, which provides protection against new and zero-hour threats; and Embedded URL Filtering Solutions to combat Web threats with a URL categorization service.

The stock decreased 2.38% or $0.05 during the last trading session, reaching $2.05. About 43,821 shares traded. CYREN Ltd. (NASDAQ:CYRN) has risen 13.76% since February 18, 2017 and is uptrending. It has underperformed by 2.94% the S&P500.

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 6 Sell and 15 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 152 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Wednesday, June 8. TD Securities maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Friday, November 3 with “Hold” rating. Mizuho maintained the shares of VRX in report on Friday, November 20 with “Buy” rating. The rating was maintained by Deutsche Bank on Monday, November 14 with “Hold”. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Monday, August 21 by H.C. Wainwright. Jefferies maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Monday, October 16 with “Buy” rating. On Tuesday, October 20 the stock rating was downgraded by IBC to “Sector Perform”. The rating was maintained by UBS with “Buy” on Friday, October 30. The firm earned “Hold” rating on Tuesday, September 20 by Deutsche Bank. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, June 29 report.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $6.58 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 4.82 P/E ratio. Diversified Products.

Investors sentiment decreased to 0.99 in Q3 2017. Its down 0.09, from 1.08 in 2017Q2. It dropped, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million shares in 2017Q2 were reported. Moreover, Morgan Stanley has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Biglari Capital Corp owns 395,000 shares. 56 are owned by First Manhattan. Pictet Asset holds 117,400 shares. Rbf Lc holds 152,400 shares or 0.28% of its portfolio. Renaissance Techs Ltd Liability reported 4.78 million shares or 0.08% of all its holdings. 59,700 were reported by Phoenix Adviser Ltd Liability. Public Sector Pension Board accumulated 591,917 shares. Fincl Bank Of Mellon holds 352,211 shares or 0% of its portfolio. Live Your Vision Llc holds 32 shares or 0% of its portfolio. Moreover, Bridgewater Assoc Lp has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Aqr Capital Limited Liability Com reported 302,414 shares. Canada Pension Plan Board stated it has 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Acadian Asset Mgmt accumulated 239,525 shares. 117,350 were accumulated by Terril Brothers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: